State Street SPDR S&P Pharmaceuticals ETF
XPH
73 hedge funds and large institutions have $117M invested in State Street SPDR S&P Pharmaceuticals ETF in 2020 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 19 increasing their positions, 17 reducing their positions, and 15 closing their positions.
894% more call options, than puts
Call options by funds: $3.33M | Put options by funds: $335K
47% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 15
12% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 17
11% more funds holding
Funds holding: 66 → 73 (+7)
7% more capital invested
Capital invested by funds: $109M → $117M (+$7.69M)
14.8% less ownership
Funds ownership: 60.45% → 45.65% (-15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$3.59M |
| 2 |
CI
CX Institutional
Auburn,
Indiana
|
+$1.67M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.35M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.15M |
| 5 |
LPL Financial
San Diego,
California
|
+$1.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$15.4M |
| 2 |
JP Morgan Chase
New York
|
-$7.32M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.03M |
| 4 |
BCM
Brookstone Capital Management
Wheaton,
Illinois
|
-$738K |
| 5 |
Goldman Sachs
New York
|
-$650K |
XPH Hedge Fund Activity: Q2 2020 in Review
73 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q2 2020, worth a combined $117M — up 7.1% from $109M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new XPH positions and 15 closed out — a net gain of 7 holders — while 19 added to existing stakes and 17 trimmed.
The largest buyer was Commonwealth Equity Services, opening a new position worth an estimated $3.59M. The largest seller was Morgan Stanley, cutting an estimated $15.4M.
- 73 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q2 2020, up from 66 in Q1 2020.
- Funds reported $117M of State Street SPDR S&P Pharmaceuticals ETF stock for Q2 2020, up 7.1% quarter-over-quarter.
- 22 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q2 2020 and 15 closed out, a net change of +7 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q2 2020 was Commonwealth Equity Services, an estimated $3.59M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q2 2020 was Morgan Stanley, an estimated $15.4M sold.
Based on aggregated 13F filings for Q2 2020.